[AGEN] Agenus Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization: 408.34 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 4.4 Change: 0.34 (8.37%)
Ext. hours: Change: 0 (0%)

chart AGEN

Refresh chart

Strongest Trends Summary For AGEN

AGEN is in the long-term down -63% below S&P in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Agenus Inc., a biopharmaceutical company, is developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines, and adjuvants. Its proprietary discovery engine Retrocyte Display is designed to generate therapeutic antibody drug candidates incorporating full-length IgG format human antibody libraries expressed in mammalian B-lineage cells. The company?s portfolio of checkpoint modulator programs is advancing in preclinical development. Its heat shock protein vaccines for cancer and infectious disease are in Phase II studies. The company?s QS-21 Stimulon adjuvant platform, which is partnered with GlaxoSmithKline and Janssen, includes various candidates in Phase III trials. In addition, it has 23 programs are in clinical development. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Fundamental Ratios
Shares Outstanding86.88 M EPS-1.28 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 28.59% Sales Growth - Q/Q144.16% P/E-2.7
P/E To EPS Growth P/S40 P/BV8.83 Price/Cash Per Share
Price/Free Cash Flow-9.95 ROA-51.88% ROE-131.58% ROI
Current Ratio4.06 Quick Ratio4.05 Long Term Debt/Equity Debt Ratio0.45
Gross Margin Operating Margin-507.29% Net Profit Margin-596.23% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities36.1 M Cash From Investing Activities14.21 M Cash From Operating Activities3.3 M Gross Profit
Net Profit-40.41 M Operating Profit-33.2 M Total Assets117.32 M Total Current Assets85.15 M
Total Current Liabilities21 M Total Debt11.5 M Total Liabilities71.07 M Total Revenue6.38 M
Technical Data
High 52 week6.04 Low 52 week1.59 Last close2.98 Last change3.11%
RSI28.15 Average true range0.22 Beta1.14 Volume925.23 K
Simple moving average 20 days-11.31% Simple moving average 50 days-2.84% Simple moving average 200 days-14.98%
Performance Data
Performance Week-17.45% Performance Month-14.61% Performance Quart37.96% Performance Half-23.2%
Performance Year-32.12% Performance Year-to-date25.21% Volatility daily3.78% Volatility weekly8.45%
Volatility monthly17.31% Volatility yearly59.97% Relative Volume223.31% Average Volume2.1 M
New High New Low

News

2019-04-13 09:30:01 | Why Is Agenus AGEN Down 13% Since Last Earnings Report?

2019-04-08 17:25:09 | Gilead Files sNDA for Label Expansion of HIV Therapy Descovy

2019-04-02 08:30:00 | Agenus Begins Dosing with Next-Gen Anti-CTLA-4 Antibody

2019-03-21 09:00:00 | Agenus Announces Clinical Appointments

2019-03-20 09:15:00 | 3 Top Growth Stocks to Buy Right Now

2019-03-14 13:34:34 | Edited Transcript of AGEN earnings conference call or presentation 14-Mar-19 12:30pm GMT

2019-03-14 11:13:03 | Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up

2019-03-14 10:55:13 | Agenus Inc AGEN Q4 2018 Earnings Conference Call Transcript

2019-03-14 09:30:01 | Agenus AGEN Reports Q4 Loss, Lags Revenue Estimates

2019-03-14 08:35:18 | Agenus: 4Q Earnings Snapshot

2019-03-14 08:00:00 | Agenus Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

2019-03-13 08:30:00 | Agenus Milestone Triggers $7.5M Payment from Gilead

2019-03-08 15:46:08 | Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy

2019-03-07 13:50:06 | Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy

2019-03-03 19:09:00 | The 3 Oldest Members of Biotech's Billion-Burned Club

2019-02-20 08:30:00 | Analysis: Positioning to Benefit within Micron Technology, Caterpillar, Agenus, Fossil Group, Marathon Petroleum, and Geo Group — Research Highlights Growth, Revenue, and Consolidated Results

2019-02-19 08:30:00 | Agenus Launches First Asset-Backed Digital-Security Offering in Healthcare

2019-02-15 11:41:00 | Agenus to Host Call to Launch First Asset-Backed Digital-Security Offering in Healthcare on February 19, 2019

2019-02-08 10:25:00 | Why Agenus Inc. Stock Took Flight in January

2019-02-05 08:43:01 | Gilead GILD Q4 Earnings Miss Estimates, Revenues Beat

2019-01-31 19:18:12 | Will Gilead GILD Q4 Earnings Disappoint on Weak HCV Sales?

2019-01-29 08:00:00 | Agenus to Launch the First Asset-Backed Digital Security Offering in Healthcare

2019-01-29 08:00:00 | Atomic Capital Kicks off Investor Forum Announcing Digital Offering for NASDAQ-Traded Biotech Group, Agenus Inc.

2019-01-24 08:30:00 | Agenus Closes $150 Million Immuno-Oncology Transaction with Gilead

2019-01-09 07:30:00 | Research Report Identifies Conagra Brands, W.R. Grace, International Flavors & Fragrances, Spirit Airlines, Sunstone Hotel Investors, and Agenus with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2019-01-08 08:38:01 | Agenus AGEN Surges: Stock Moves 9.4% Higher

2019-01-07 12:17:00 | Why Agenus Stock Is Spiking Today

2019-01-06 10:00:00 | All the Pre-JPM News Healthcare Investors Need to Know

2019-01-04 08:31:01 | Are Options Traders Betting on a Big Move in Agenus AGEN Stock?

2019-01-03 16:31:00 | Why Celgene, Agenus, and Incyte Jumped Today

2019-01-03 16:22:00 | Here's Why Agenus Shares Rose as Much as 13.5% Today

2019-01-03 11:30:00 | Agenus Awarded Grant to Enable QS-21 Innovations

2018-12-26 10:32:00 | 3 Biotech Stocks That Are Too Cheap to Ignore

2018-12-26 09:34:02 | Biotech Stock Roundup: ALXN, ACOR Drugs' Get FDA Nod, AGEN up on GILD Deal

2018-12-23 09:03:00 | 2 Beaten-Down Biotech Stocks That Look Like Bargains Now

2018-12-21 09:19:02 | Agenus' Stock Up 23% on Immuno-Oncology Deal With Gilead

2018-12-21 08:00:00 | Major Biotech Deals Making Sector Red Hot

2018-12-20 12:48:00 | Why Agenus Stock Is Soaring Today

2018-12-20 09:30:00 | 4 Biotech Stocks Making Moves on Thursday December 20, 2018

2018-12-20 08:28:00 | Agenus stock shoots up 60% after announcing drug development deal with Gilead

2018-12-20 07:48:55 | Gilead, Agenus sign deal to develop immuno-oncology therapies

2018-12-20 07:30:00 | Gilead And Agenus Enter into Collaboration to Develop Immuno-Oncology Therapies

2018-12-17 07:00:00 | Today's Research Reports on Trending Tickers: Amarin Corporation and Agenus

2018-12-06 09:30:02 | Why Is Agenus AGEN Up 11.6% Since Last Earnings Report?

2018-12-05 22:18:00 | Here's Why Agenus Stock Popped 51.6% in November

2018-12-04 12:00:00 | Orchestra BioMed™ Appoints C. Evan Ballantyne as Chief Financial Officer

2018-11-13 16:05:00 | Agenus Elects New Board Member Dr. Allison Jeynes-Ellis and Appoints Chief Operating Officer Dr. Jennifer Buell

2018-11-13 11:30:00 | Agenus to Present at the 2018 Jefferies London Healthcare Conference

2018-11-09 07:55:00 | Report: Developing Opportunities within Agenus, Kirkland's, Preferred Apartment Communities, Gulfport Energy, ProAssurance, and US Ecology — Future Expectations, Projections Moving into 2018

2018-11-08 16:28:09 | Agenus AGEN Q3 Loss Wider Than Expected, Pipeline in Focus